← Back to Search

Local Anesthetic

Anesthetic Techniques for Pain and Anesthesia

N/A
Waitlist Available
Led By Roya Yumul, MD, PhD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of abdominal tumor scheduled for exploratory laparotomy with study surgeon
Must be able to have an epidural
Must not have
Morbid obesity (BMI > 40 kg/m2) AND/OR weight > 150 kg
HIV or other immunosuppressive condition
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare the effects of two anesthetic techniques on natural killer cells in patients undergoing abdominal surgery.

Who is the study for?
This trial is for adults aged 18-80 with an abdominal tumor scheduled for exploratory surgery, who can have an epidural. It's not for those with severe health issues like heart disease, uncontrolled high blood pressure, significant psychological disorders, or certain medication use. Pregnant women and individuals with obesity or organ failure are also excluded.
What is being tested?
The study compares the effects of two anesthesia methods using Bupivacaine alone versus Bupivacaine combined with Fentanyl on natural killer cells in patients having abdominal surgery. It's a pilot study where participants are randomly assigned to one of these standard treatments without knowing which one they receive.
What are the potential side effects?
Possible side effects from the interventions may include typical reactions to local anesthetics such as numbness, weakness, low blood pressure, and nausea. Fentanyl might cause drowsiness, nausea, confusion or respiratory depression.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for surgery to explore my abdominal tumor.
Select...
I can have an epidural.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a BMI over 40 or weigh more than 150 kg.
Select...
I have HIV or another condition that weakens my immune system.
Select...
I am allergic or cannot tolerate fentanyl or bupivacaine.
Select...
My blood pressure is not higher than 140/90.
Select...
I have a heart condition known as prolonged QT syndrome.
Select...
I am not taking medications known to affect heart rhythm.
Select...
I do not have active liver failure or cirrhosis.
Select...
My blood levels of potassium, magnesium, or calcium are low and not corrected.
Select...
I take more than 30mg of oxycodone or equivalent daily.
Select...
I am experiencing significant weight loss and muscle wasting.
Select...
I have used corticosteroids for more than 2 weeks in the last 6 months.
Select...
I do not have an infection or skin issue where my epidural was placed.
Select...
I cannot or do not want to have an epidural for pain control due to back issues or personal choice.
Select...
I cannot tolerate certain pain medications given through the spine.
Select...
I have had a heart attack or abnormal heart stress test in the last 3 months.
Select...
My kidney function is impaired with creatinine over 2.0 mg/dL.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Natural Killer Cell Cytotoxicty

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 'Bupivacaine + Fentanyl' (Opioid Group)Experimental Treatment1 Intervention
Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
Group II: Bupivacaine (Local Anesthetic Group)Active Control1 Intervention
Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine + Fentanyl
2022
N/A
~40

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
509 Previous Clinical Trials
162,659 Total Patients Enrolled
Roya Yumul, MD, PhDPrincipal InvestigatorProgram Director, Department of Anesthesiology
8 Previous Clinical Trials
406 Total Patients Enrolled

Media Library

Bupivacaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT02669186 — N/A
Anesthesia Research Study Groups: 'Bupivacaine + Fentanyl' (Opioid Group), Bupivacaine (Local Anesthetic Group)
Anesthesia Clinical Trial 2023: Bupivacaine Highlights & Side Effects. Trial Name: NCT02669186 — N/A
Bupivacaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02669186 — N/A
~3 spots leftby Dec 2025